Premium
Paeonol ameliorates murine alcohol liver disease via mycobiota‐mediated Dectin‐1/IL‐1β signaling pathway
Author(s) -
Wu Jiadi,
Wu Daqiang,
Ma Kelong,
Wang Tianming,
Shi Gaoxiang,
Shao Jing,
Wang Changzhong,
Yan Guiming
Publication year - 2020
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1002/jlb.3ma0120-325rr
Subject(s) - mycobiota , paeonol , biology , dysbiosis , alcoholic liver disease , pharmacology , signal transduction , liver injury , microbiology and biotechnology , immunology , gut flora , biochemistry , medicine , pathology , botany , alternative medicine , cirrhosis
Alcoholic liver disease (ALD) is caused by long‐term consumption of alcohol and has become an important social and medical problem. Intestinal fungal flora (mycobiota) play an important role in ALD, so we used the mycobiota as an entry point to explore the mechanism of action of Paeonol against ALD. Here, we found that Paeonol is effective against ALD inflammatory lesions and relieves liver fat lesions. Furthermore, we found that after the treatment of Paeonol, the fungal dysbiosis is improved, and the fungal abundance is reduced, and the translocation of β‐glucan to the liver and its mediated Dectin‐1/IL‐1β signaling pathway is blocked. Our study shows that paeonol ameliorated acute ALD‐related inflammatory injury to the liver by alleviating intestinal fungal dysbiosis and inhibiting the mycobiota‐mediated Dectin‐1/IL‐1β signaling pathway.